您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
LRRC15/LIB His Tag Protein, Human

LRRC15/LIB His Tag Protein, Human

货号: UA010915
价格: 960
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • 分子别名

    Leucine-rich repeat-containing protein 15, Leucine-rich repeat protein induced by beta-amyloid homolog (hLib), LRRC15, LIB
  • Accession

    Q8TF66-1
  • 表达序列

    Tyr22-Gly538, with C-terminal His
  • 表达宿主

    HEK293
  • 分子量

    82-93kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE&>95% by SEC-HPLC
  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, 5% trehalose, pH7.4
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.

    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.

    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    O'Prey J, Wilkinson S, Ryan KM. Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy. J Virol 2008;82:5933–9. 2. Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov 2020;10:232–53. 17. Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res 2018;78:4059–72.

  • 稀释度

背景介绍
  • The leucine-rich repeat-containing protein 15(LRRC15)is a transmembrane protein located on chromosome 3 at 3q29 that belongs to the LRR superfamily, which is involved in cell–cell and cell–ECM interactions. LRRC15 highly expressed in CAFs within the stroma of numerous solid tumors and directly expressed in mesenchymal tumors such as glioblastoma, sarcomas, and melanoma. LRRC15 expression has been shown to be upregulated in C6 astrocytoma cells in response to proinflammatory cytokines (TNFα, IL1β, and IFNγ) and upregulated in fibroblasts in response to TGFβ. LRRC15 is involved in cell–cell and cell–matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors.

  • 电泳JSON

    • 1μg (R: reducing condition, N: non-reducing condition).

  • 体积排阻色谱JSON(SEC-HPLC)

    • SEC-HPLC>95%

  • ELISA

    • Immobilized LRRC15/LIB His Tag, Human (Cat. No. UA010915) at 10.0μg/mL (100μL/well) can bind Samrotamab (Cat. No. UA011138) with EC50 of 6.86-9.73ng/mL.